Raja P, Hawker R E, Chaikitpinyo A, Cooper S G, Lau K C, Nunn G R, Cartmill T B, Sholler G F
Adolph Basser Institute of Cardiology, Royal Alexandra Hospital for Children, Camperdown, Sydney, Australia.
Br Heart J. 1994 Sep;72(3):261-5. doi: 10.1136/hrt.72.3.261.
To assess the effectiveness and safety of amiodarone in the treatment of junctional ectopic tachycardia (JET) after open heart surgery in children.
Between January 1990 and December 1991, 16 consecutive patients aged 6 days to 14 years with JET associated with significant haemodynamic impairment after cardiopulmonary bypass were treated with amiodarone as the principal antiarrhythmic drug.
Amiodarone 5 mg/kg was administered intravenously over one hour and the same dose was subsequently infused over 12 hours. This was reviewed every 12 hours and repeated as necessary until a satisfactory heart rate and stable haemodynamics were achieved. Atrial pacing was used whenever possible to provide atrioventricular synchrony.
Except for one patient with a JET rate of 160/min, the maximum JET rate ranged from 180/min to 245/min with a mean(SD) of 200 (20)/min. After amiodarone, the heart rates reduced to a mean(SD) of 170 (20), 164 (27), 158 (27), 157 (24), and 153 (19)/min at two, four, eight, 12, and 24 hours respectively. A reduction in tachycardia rate allowing atrial pacing was achieved in 10 patients by two hours. Haemodynamic variables improved in most patients with an increase in mean systolic blood pressure by an average of 15 mm Hg and a decrease in atrial filling pressures by an average of 3.5 mm Hg at four hours after amiodarone administration. There were three deaths: one was a moribund patient who died soon after the onset of JET and the other two deaths were not directly related to JET.
Late bradycardia with hypotension was recorded in one patient. Asymptomatic late sinus bradycardia was seen in several others.
Amiodarone can be used safely and effectively to control JET with haemodynamic improvement in most patients. The addition of atrial pacing confers the advantage of atrioventricular synchrony.
评估胺碘酮治疗小儿心脏直视手术后交界性异位性心动过速(JET)的有效性和安全性。
1990年1月至1991年12月期间,16例年龄在6天至14岁之间、体外循环后出现JET且伴有明显血流动力学损害的连续患者,接受胺碘酮作为主要抗心律失常药物治疗。
胺碘酮5mg/kg在1小时内静脉给药,随后相同剂量在12小时内输注。每12小时评估一次,必要时重复给药,直至达到满意的心率和稳定的血流动力学。尽可能采用心房起搏以实现房室同步。
除1例JET心率为160次/分钟的患者外,JET最高心率范围为180次/分钟至245次/分钟,平均(标准差)为200(20)次/分钟。使用胺碘酮后,心率在2小时、4小时、8小时、12小时和24小时分别降至平均(标准差)170(20)、164(27)、158(27)、157(24)和153(19)次/分钟。10例患者在2小时内心动过速率降低,从而能够进行心房起搏。大多数患者的血流动力学变量得到改善,胺碘酮给药后4小时,平均收缩压平均升高15mmHg,心房充盈压平均降低3.5mmHg。有3例死亡:1例为濒死患者,在JET发作后不久死亡,另外2例死亡与JET无直接关系。
1例患者出现迟发性心动过缓伴低血压。其他几例患者出现无症状性迟发性窦性心动过缓。
胺碘酮可安全有效地用于控制JET,多数患者血流动力学得到改善。加用心房起搏可带来房室同步的优势。